The role of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: Central mediators of pathophysiology and antidepressant activity?

Neuroscience and Biobehavioral Reviews

Volumn 52, Issue , 2015, Pages 193-206

  Freudenberg, Florian ^a   Celikel, Tansu ^b   Reif, Andreas ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b RADBOUD UNIVERSITY   (Netherlands)

Author keywords

AMPA receptors; Ampakines; Depression; Glutamatergic synapse; Ketamine; MDD; Neuroplasticity; PDZ domain; Psychiatric disorders; Synaptic plasticity

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; AMPA RECEPTOR; AMPA RECEPTOR AGONIST; AMPA RECEPTOR ANTAGONIST; ANIRACETAM; BRAIN DERIVED NEUROTROPHIC FACTOR; CX 731; DESIPRAMINE; DIZOCILPINE; FARAMPATOR; FLUOXETINE; GLUTAMIC ACID; IMIPRAMINE; IONOTROPIC RECEPTOR; KETAMINE; LITHIUM; MAPROTILINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N [2 [4 (3 THIENYL)PHENYL]PROPYL] 2 PROPANESULFONAMIDE; N [2 [4 (4 CYANOPHENYL)PHENYL]PROPYL] 2 PROPANESULFONAMIDE; PIRACETAM; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT;

ANTIDEPRESSANT ACTIVITY; CAUDATE NUCLEUS; DENTATE GYRUS; DEPRESSION; DISEASE COURSE; ENTORHINAL CORTEX; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; HUMAN; NERVE CELL PLASTICITY; NONHUMAN; NUCLEUS ACCUMBENS; PATHOPHYSIOLOGY; PATIENT CARE; PERIRHINAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CENTRAL NERVOUS SYSTEM; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS; CENTRAL NERVOUS SYSTEM; DEPRESSION; HUMANS; KETAMINE; NEURONAL PLASTICITY; RECEPTORS, AMPA;

EID: 84925446540     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2015.03.005     Document Type: Review

References (145)

1. aan het Rot M., Collins K.A., Murrough J.W., Perez A.M., Reich D.L., Charney D.S., Mathew S.J. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol. Psychiatry 2010, 67:139-145. 10.1016/j.biopsych.2009.08.038.
2. Adamczyk A., Mejias R., Takamiya K., Yocum J., Krasnova I.N., Calderon J., Cadet J.L., Huganir R.L., Pletnikov M.V., Wang T. GluA3-deficiency in mice is associated with increased social and aggressive behavior and elevated dopamine in striatum. Behav. Brain Res. 2012, 229:265-272. 10.1016/j.bbr.2012.01.007.
3. Alt A., Witkin J., Bleakman D. AMPA receptor potentiators as novel antidepressants. Curr. Pharm. Des. 2005, 11:1511-1527. 10.2174/1381612053764814.
4. Ampuero E., Rubio F.J., Falcon R., Sandoval M., Diaz-Veliz G., Gonzalez R.E., Earle N., Dagnino-Subiabre A., Aboitiz F., Orrego F., Wyneken U. Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex. Neuroscience 2010, 169:98-108. 10.1016/j.neuroscience.2010.04.035.
5. Andrásfalvy B.K., Smith M.A., Borchardt T., Sprengel R., Magee J.C. Impaired regulation of synaptic strength in hippocampal neurons from GluR1-deficient mice. J. Physiol. 2003, 552:35-45. 10.1113/jphysiol.2003.045575.
6. Andreasen J.T., Fitzpatrick C.M., Larsen M., Skovgaard L., Nielsen S.D., Clausen R.P., Troelsen K., Pickering D.S. Differential role of AMPA receptors in mouse tests of antidepressant and anxiolytic action. Brain Res. 2015, 1-10. 10.1016/j.brainres.2015.01.001.
7. Arai A., Kessler M. Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. Curr. Drug Targets 2007, 8:583-602. 10.2174/138945007780618490.
8. Autry A.E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P., Kavalali E.T., Monteggia L.M. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475:91-95. 10.1038/nature10130.
9. Bai F., Li X., Clay M., Lindstrom T., Skolnick P. Intra- and interstrain differences in models of behavioral despair. Pharmacol. Biochem. Behav. 2001, 70:187-192. 10.1016/S0091-3057(01)00599-8.
10. Bannerman D.M., Deacon R.M.J., Brady S., Bruce A., Sprengel R., Seeburg P.H., Rawlins J.N.P. A comparison of GluR-A-deficient and wild-type mice on a test battery assessing sensorimotor, affective, and cognitive behaviors. Behav. Neurosci. 2004, 118:643-647. 10.1037/0735-7044.118.3.643.
11. Barbon A., Caracciolo L., Orlandi C., Musazzi L., Mallei A., La Via L., Bonini D., Mora C., Tardito D., Gennarelli M., Racagni G., Popoli M., Barlati S. Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels. Neurochem. Int. 2011, 59:896-905. 10.1016/j.neuint.2011.07.013.
12. Bartanusz V., Aubry J., Pagliusi S., Jezova D., Baffi J., Kiss J.Z. Stress-induced changes in messenger RNA levels of N-methyl-d-aspartate and AMPA receptor subunits in selected regions of the rat hippocampus and hypothalamus. Neuroscience 1995, 66:247-252. 10.1016/0306-4522(95)00084-V.
13. Beneyto M., Kristiansen L.V., Oni-Orisan A., McCullumsmith R.E., Meador-Woodruff J.H. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007, 32:1888-1902. 10.1038/sj.npp.1301312.
14. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000, 47:351-354. 10.1016/S0006-3223(99)00230-9.
15. Bleakman D., Alt A., Witkin J. AMPA receptors in the therapeutic management of depression. CNS Neurol. Disord.-Drug Targets 2007, 6:117-126. 10.2174/187152707780363258.
16. Bonanno G., Giambelli R., Raiteri L., Tiraboschi E., Zappettini S., Musazzi L., Raiteri M., Racagni G., Popoli M. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J. Neurosci. 2005, 25:3270-3279. 10.1523/JNEUROSCI.5033-04.2005.
17. Caputi A., Fuchs E.C., Allen K., Le Magueresse C., Monyer H. Selective reduction of AMPA currents onto hippocampal interneurons impairs network oscillatory activity. PLoS ONE 2012, 7:e37318. 10.1371/journal.pone.0037318.
18. Caudal D., Godsil B.P., Mailliet F., Bergerot D., Jay T.M. Acute stress induces contrasting changes in AMPA receptor subunit phosphorylation within the prefrontal cortex, amygdala and hippocampus. PLoS ONE 2010, 5. 10.1371/journal.pone.0015282.
19. Chourbaji S., Vogt M.A., Fumagalli F., Sohr R., Frasca A., Brandwein C., Hörtnagl H., Riva M.A., Sprengel R., Gass P. AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression. FASEB J. 2008, 22:3129-3134. 10.1096/fj. 08-106450.
20. Citri A., Malenka R.C. Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology 2008, 33:18-41. 10.1038/sj.npp.1301559.
21. Collingridge G.L., Olsen R.W., Peters J., Spedding M. A nomenclature for ligand-gated ion channels. Neuropharmacology 2009, 56:2-5. 10.1016/j.neuropharm.2008.06.063.
22. Covington H.E., Vialou V., Nestler E.J. From synapse to nucleus: novel targets for treating depression. Neuropharmacology 2010, 58:683-693. 10.1016/j.neuropharm.2009.12.004.
23. Dev K.K. Making protein interactions druggable: targeting PDZ domains. Nat. Rev. Drug Discov. 2004, 3:1047-1056. 10.1038/nrd1578.
24. Dingledine R., Borges K., Bowie D., Traynelis S.F. The glutamate receptor ion channels. Pharmacol. Rev. 1999, 51:7-61.
25. Doucet M.V., Levine H., Dev K.K., Harkin A. Small molecule inhibitors at the PSD-95/nNOS interface have antidepressant-like properties in mice. Neuropsychopharmacology 2013, 1-10. 10.1038/npp.2013.57.
26. Duman R.S., Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci. 2012, 35:47-56. 10.1016/j.tins.2011.11.004.
27. Durand C.M., Betancur C., Boeckers T.M., Bockmann J., Chaste P., Fauchereau F., Nygren G., Rastam M., Gillberg I.C., Anckarsäter H., Sponheim E., Goubran-Botros H., Delorme R., Chabane N., Mouren-Simeoni M.-C., de Mas P., Bieth E., Rogé B., Héron D., Burglen L., Gillberg C., Leboyer M., Bourgeron T. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat. Genet. 2007, 39:25-27. 10.1038/ng1933.
28. Duric V., Banasr M., Stockmeier C.A., Simen A.A., Newton S.S., Overholser J.C., Jurjus G.J., Dieter L., Duman R.S. Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. Int. J. Neuropsychopharmacol. 2013, 16:69-82. 10.1017/S1461145712000016.
29. Farley S., Apazoglou K., Witkin J.M., Giros B., Tzavara E.T. Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. Int. J. Neuropsychopharmacol. 2010, 13:1207-1218. 10.1017/S1461145709991076.
30. Ferraguti F., Shigemoto R. Metabotropic glutamate receptors. Cell Tissue Res. 2006, 326:483-504. 10.1007/s00441-006-0266-5.
31. Feyder M., Wiedholz L., Sprengel R., Holmes A. Impaired associative fear learning in mice with complete loss or haploinsufficiency of AMPA GluR1 receptors. Front. Behav. Neurosci. 2007, 1:1-5. 10.3389/neuro.08/004.2007.
32. Feyissa A.M., Chandran A., Stockmeier C.A., Karolewicz B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:70-75. 10.1016/j.pnpbp.2008.10.005.
33. Fitzgerald P.J., Barkus C., Feyder M., Wiedholz L.M., Chen Y.-C., Karlsson R.-M., Machado-Vieira R., Graybeal C., Sharp T., Zarate C., Harvey-White J., Du J., Sprengel R., Gass P., Bannerman D., Holmes A. Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder?. Neurobiol. Dis. 2010, 40:608-621. 10.1016/j.nbd.2010.08.005.
34. 2+-dependent release in intractable depression assessed antemortem. Brain Res. 1989, 494:315-324. 10.1016/0006-8993(89)90600-8.
35. Freudenberg F., Marx V., Mack V., Layer L.E., Klugmann M., Seeburg P.H., Sprengel R., Celikel T. GluA1 and its PDZ-interaction: a role in experience-dependent behavioral plasticity in the forced swim test. Neurobiol. Dis. 2013, 52:160-167. 10.1016/j.nbd.2012.12.003.
36. Freudenberg F., Marx V., Seeburg P.H., Sprengel R., Celikel T. Circuit mechanisms of GluA1-dependent spatial working memory. Hippocampus 2013, 23:1359-1366. 10.1002/hipo.22184.
37. Frye M.A., Tsai G.E., Huggins T., Coyle J.T., Post R.M. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol. Psychiatry 2007, 61:162-166. 10.1016/j.biopsych.2006.01.024.
38. Fuchs E.C., Zivkovic A.R., Cunningham M.O., Middleton S., Lebeau F.E.N., Bannerman D.M., Rozov A., Whittington M.A., Traub R.D., Rawlins J.N.P., Monyer H. Recruitment of parvalbumin-positive interneurons determines hippocampal function and associated behavior. Neuron 2007, 53:591-604. 10.1016/j.neuron.2007.01.031.
39. Gallassi R., Di Sarro R., Morreale A., Amore M. Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy. J. Affect. Disord. 2006, 91:243-250. 10.1016/j.jad.2006.01.018.
40. Gauthier J., Champagne N., Lafrenière R.G., Xiong L., Spiegelman D., Brustein E., Lapointe M., Peng H., CÔté M., Noreau A., Hamdan F.F., Addington A.M., Rapoport J.L., Delisi L.E., Krebs M.-O., Joober R., Fathalli F., Mouaffak F., Haghighi A.P., Néri C., Dubé M.-P., Samuels M.E., Marineau C., Stone E.A., Awadalla P., Barker P.A., Carbonetto S., Drapeau P., Rouleau G.A. De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:7863-7868. 10.1073/pnas.0906232107.
41. Gerlai R., Henderson J.T., Roder J.C., Jia Z. Multiple behavioral anomalies in GluR2 mutant mice exhibiting enhanced LTP. Behav. Brain Res. 1998, 95:37-45. 10.1016/S0166-4328(98)00002-3.
42. Gibbons A.S., Brooks L., Scarr E., Dean B. AMPA receptor expression is increased post-mortem samples of the anterior cingulate from subjects with major depressive disorder. J. Affect. Disord. 2012, 136:1232-1237. 10.1016/j.jad.2011.10.001.
43. Gould T.D., O'Donnell K.C., Dow E.R., Du J., Chen G., Manji H.K. Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. Neuropharmacology 2008, 54:577-587. 10.1016/j.neuropharm.2007.11.002.
44. Groc L., Choquet D., Chaouloff F. The stress hormone corticosterone conditions AMPAR surface trafficking and synaptic potentiation. Nat. Neurosci. 2008, 11:868-870. 10.1038/nn.2150.
45. Guire E.S., Oh M.C., Soderling T.R., Derkach V.a. Recruitment of calcium-permeable AMPA receptors during synaptic potentiation is regulated by CaM-kinase I. J. Neurosci. 2008, 28:6000-6009. 10.1523/JNEUROSCI.0384-08.2008.
46. Haering S.C., Tapken D., Pahl S., Hollmann M. Auxiliary subunits: shepherding AMPA receptors to the plasma membrane. Membranes (Basel) 2014, 4:469-490. 10.3390/membranes4030469.
47. Hashimoto K., Sawa A., Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry 2007, 62:1310-1316. 10.1016/j.biopsych.2007.03.017.
48. Hasler G., Drevets W.C., Manji H.K., Charney D.S. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004, 29:1765-1781. 10.1038/sj.npp.1300506.
49. Hayashi Y., Shi S.H., Esteban J.A., Piccini A., Poncer J.C., Malinow R. Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction. Science 2000, 287:2262-2267. 10.1126/science.287.5461.2262.
50. Hollis F., Isgor C., Kabbaj M. The consequences of adolescent chronic unpredictable stress exposure on brain and behavior. Neuroscience 2013, 249:232-241. 10.1016/j.neuroscience.2012.09.018.
51. Humeau Y., Reisel D., Johnson A.W., Borchardt T., Jensen V., Gebhardt C., Bosch V., Gass P., Bannerman D.M., Good M.A., Hvalby Ø., Sprengel R., Lüthi A. A pathway-specific function for different AMPA receptor subunits in amygdala long-term potentiation and fear conditioning. J. Neurosci. 2007, 27:10947-10956. 10.1523/JNEUROSCI.2603-07.2007.
52. Ibrahim L., Diaz Granados N., Jolkovsky L., Brutsche N., Luckenbaugh D.A., Herring W.J., Potter W.Z., Zarate C.A. A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J. Clin. Psychopharmacol. 2012, 32:551-557. 10.1097/JCP.0b013e31825d70d6.
53. Ibrahim L., Diazgranados N., Luckenbaugh D.A., Machado-Vieira R., Baumann J., Mallinger A.G., Zarate C.A. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:1155-1159. 10.1016/j.pnpbp.2011.03.019.
54. Jensen V., Kaiser K.M.M., Borchardt T., Adelmann G., Rozov A., Burnashev N., Brix C., Frotscher M., Andersen P., Hvalby Ø., Sakmann B., Seeburg P.H., Sprengel R. A juvenile form of postsynaptic hippocampal long-term potentiation in mice deficient for the AMPA receptor subunit GluR-A. J. Physiol. 2003, 553:843-856. 10.1113/jphysiol.2003.053637.
55. Jia Z., Agopyan N., Miu P., Xiong Z., Henderson J., Gerlai R., Taverna F.a., Velumian A., MacDonald J., Carlen P., Abramow-Newerly W., Roder J. Enhanced LTP in mice deficient in the AMPA receptor GluR2. Neuron 1996, 17:945-956. 10.1016/S0896-6273(00)80225-1.
56. Kallarackal A.J., Kvarta M.D., Cammarata E., Jaberi L., Cai X., Bailey A.M., Thompson S.M. Chronic stress induces a selective decrease in AMPA receptor-mediated synaptic excitation at hippocampal temporoammonic-CA1 synapses. J. Neurosci. 2013, 33:15669-15674. 10.1523/JNEUROSCI.2588-13.2013.
57. Karasawa J., Shimazaki T., Kawashima N., Chaki S. AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res. 2005, 1042:92-98. 10.1016/j.brainres.2005.02.032.
58. Karst H., Berger S., Turiault M., Tronche F., Schütz G., Joëls M. Mineralocorticoid receptors are indispensable for nongenomic modulation of hippocampal glutamate transmission by corticosterone. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:19204-19207. 10.1073/pnas.0507572102.
59. Kato A.S., Gill M.B., Ho M.T., Yu H., Tu Y., Siuda E.R., Wang H., Qian Y.-W., Nisenbaum E.S., Tomita S., Bredt D.S. Hippocampal AMPA receptor gating controlled by both TARP and cornichon proteins. Neuron 2010, 68:1082-1096. 10.1016/j.neuron.2010.11.026.
60. Kato A.S., Gill M.B., Yu H., Nisenbaum E.S., Bredt D.S. TARPs differentially decorate AMPA receptors to specify neuropharmacology. Trends Neurosci. 2010, 33:241-248. 10.1016/j.tins.2010.02.004.
61. Kendler K.S., Karkowski L.M., Prescott C.A. The assessment of dependence in the study of stressful life events: validation using a twin design. Psychol. Med. 1999, 29:1455-1460. 10.1017/S0033291798008198.
62. Kessels H.W., Malinow R. Synaptic AMPA receptor plasticity and behavior. Neuron 2009, 10.1016/j.neuron.2009.01.015.
63. Kessler R.C. The effects of stressful life events on depression. Annu. Rev. Psychol. 1997, 48:191-214. 10.1146/annurev.psych.48.1.191.
64. Kew J.N.C., Kemp J.A. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl.) 2005, 179:4-29. 10.1007/s00213-005-2200-z.
65. Knapp R.J., Goldenberg R., Shuck C., Cecil A., Watkins J., Miller C., Crites G., Malatynska E. Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur. J. Pharmacol. 2002, 440:27-35. 10.1016/S0014-2999(02)01338-9.
66. Koike H., Chaki S. Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Behav. Brain Res. 2014, 271:111-115. 10.1016/j.bbr.2014.05.065.
67. Koike H., Iijima M., Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav. Brain Res. 2011, 224:107-111. 10.1016/j.bbr.2011.05.035.
68. Krishnan V., Nestler E.J. Animal models of depression: molecular perspectives. Mol. Funct. Model. Neuropsychiatry 2011, 121-147. 10.1007/7854.
69. Krugers H.J., Hoogenraad C.C., Groc L. Stress hormones and AMPA receptor trafficking in synaptic plasticity and memory. Nat. Rev. Neurosci. 2010, 11:675-681. 10.1038/nrn2913.
70. Lee H.K., Takamiya K., Han J.S., Man H., Kim C.H., Rumbaugh G., Yu S., Ding L., He C., Petralia R.S., Wenthold R.J., Gallagher M., Huganir R.L. Phosphorylation of the AMPA receptor GluR1 subunit is required for synaptic plasticity and retention of spatial memory. Cell 2003, 112:631-643. 10.1016/S0092-8674(03)00122-3.
71. Lépine J.-P., Briley M. The increasing burden of depression. Neuropsychiatr. Dis. Treat. 2011, 7:3-7. 10.2147/NDT.S19617.
72. Li N., Lee B., Liu R.-J., Banasr M., Dwyer J.M., Iwata M., Li X.-Y., Aghajanian G., Duman R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964. 10.1126/science.1190287.
73. Li X., Tizzano J.P., Griffey K., Clay M., Lindstrom T., Skolnick P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 2001, 40:1028-1033. 10.1016/S0028-3908(00)00194-5.
74. Li X., Witkin J.M., Need A.B., Skolnick P. Enhancement of antidepressant potency by a potentiator of AMPA receptors. Cell. Mol. Neurobiol. 2003, 23:419-430. 10.1023/A:1023648923447.
75. Lu W., Shi Y., Jackson A.C., Bjorgan K., During M.J., Sprengel R., Seeburg P.H., Nicoll R.A. Subunit composition of synaptic AMPA receptors revealed by a single-cell genetic approach. Neuron 2009, 62:254-268. 10.1016/j.neuron.2009.02.027.
76. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., Manji H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 2008, 63:349-352. 10.1016/j.biopsych.2007.05.028.
77. Maksimovic M., Vekovischeva O.Y., Aitta-aho T., Korpi E.R. Chronic treatment with mood-stabilizers attenuates abnormal hyperlocomotion of GluA1-subunit deficient mice. PLoS ONE 2014, 9:e100188. 10.1371/journal.pone.0100188.
78. Malatynska E., Goldenberg R., Shuck L., Haque A., Zamecki P., Crites G., Schindler N., Knapp R.J. Reduction of submissive behavior in rats: a test for antidepressant drug activity. Pharmacology 2002, 64:8-17. 10.1159/000056145.
79. Malatynska E., Knapp R.J. Dominant-submissive behavior as models of mania and depression. Neurosci. Biobehav. Rev. 2005, 29:715-737. 10.1016/j.neubiorev.2005.03.014.
80. Malinow R., Malenka R.C. AMPA receptor trafficking and synaptic plasticity. Annu. Rev. Neurosci. 2002, 25:103-126. 10.1146/annurev.neuro.25.112701.142758.
81. Marazziti D., Consoli G., Picchetti M., Carlini M., Faravelli L. Cognitive impairment in major depression. Eur. J. Pharmacol. 2010, 626:83-86. 10.1016/j.ejphar.2009.08.046.
82. Martin S., Henley J.M., Holman D., Zhou M., Wiegert O., van Spronsen M., Joëls M., Hoogenraad C.C., Krugers H.J. Corticosterone alters AMPAR mobility and facilitates bidirectional synaptic plasticity. PLoS ONE 2009, 4:e4714. 10.1371/journal.pone.0004714.
83. Martínez-Turrillas R., Del Río J., Frechilla D. Sequential changes in BDNF mRNA expression and synaptic levels of AMPA receptor subunits in rat hippocampus after chronic antidepressant treatment. Neuropharmacology 2005, 49:1178-1188. 10.1016/j.neuropharm.2005.07.006.
84. Martínez-Turrillas R., Frechilla D., Del Río J. Chronic antidepressant treatment increases the membrane expression of AMPA receptors in rat hippocampus. Neuropharmacology 2002, 43:1230-1237. 10.1016/S0028-3908(02)00299-X.
85. Mathew S.J., Shah A., Lapidus K., Clark C., Jarun N., Ostermeyer B., Murrough J.W. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 2012, 26:189-204. 10.2165/11599770-000000000-00000.
86. Mayer M.L. Glutamate receptor ion channels. Curr. Opin. Neurobiol. 2005, 15:282-288. 10.1016/j.conb.2005.05.004.
87. Mayer M.L., Armstrong N. Structure and function of glutamate receptor ion channels. Annu. Rev. Physiol. 2004, 66:161-181. 10.1146/annurev.physiol.66.050802.084104.
88. Meador-Woodruff J.H., Hogg A.J., Smith R.E. Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res. Bull. 2001, 55:631-640. 10.1016/S0361-9230(01)00523-8.
89. Meng Y., Zhang Y., Jia Z. Synaptic transmission and plasticity in the absence of AMPA glutamate receptor GluR2 and GluR3. Neuron 2003, 39:163-176. 10.1016/S0896-6273(03)00368-4.
90. Milanese M., Tardito D., Musazzi L., Treccani G., Mallei A., Bonifacino T., Gabriel C., Mocaer E., Racagni G., Popoli M., Bonanno G. Chronic treatment with agomelatine or venlafaxine reduces depolarization-evoked glutamate release from hippocampal synaptosomes. BMC Neurosci. 2013, 14:75. 10.1186/1471-2202-14-75.
91. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 1997, 17:2921-2927.
92. Monleon S., Parra A., Simon V.M., Brain P.F., D'Aquila P., Willner P. Attenuation of sucrose consumption in mice by chronic mild stress and its restoration by imipramine. Psychopharmacology (Berl.) 1995, 117:453-457. 10.1007/BF02246218.
93. Nations K.R., Dogterom P., Bursi R., Schipper J., Greenwald S., Zraket D., Gertsik L., Johnstone J., Lee A., Pande Y., Ruigt G., Ereshefsky L. Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial. J. Psychopharmacol. 2012, 26:1525-1539. 10.1177/0269881112458728.
94. Naylor P., Stewart C.A., Wright S.R., Carl A., Pearson R., Reid I.C. Repeated ECS induces GluR1 mRNA but not NMDAR1A-G mRNA in the rat hippocampus. Mol. Brain Res. 1996, 35:349-353. 10.1016/0169-328X(95)00264-S.
95. Niswender C.M., Conn P.J. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 2010, 50:295-322. 10.1146/annurev.pharmtox.011008.145533.
96. Noga J.T., Wang H. Further postmortem autoradiographic studies of AMPA receptor binding in schizophrenia. Synapse 2002, 45:250-258. 10.1002/syn.10106.
97. O'Neill M., Bleakman D., Zimmerman D., Nisenbaum E. AMPA receptor potentiators for the treatment of CNS disorders. Curr. Drug Target-CNS Neurol. Disord. 2004, 3:181-194. 10.2174/1568007043337508.
98. Padovan C.M., Guimarães F.S. Antidepressant-like effects of NMDA-receptor antagonist injected into the dorsal hippocampus of rats. Pharmacol. Biochem. Behav. 2004, 77:15-19. 10.1016/j.pbb.2003.09.015.
99. Papp M., Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur. J. Pharmacol. 1994, 263:1-7. 10.1016/0014-2999(94)90516-9.
100. Papp M., Moryl E. Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and d-cycloserine in an animal model of depression. Eur. J. Pharmacol. 1996, 316:145-151. 10.1016/S0014-2999(96)00675-9.
101. Pariante C.M., Lightman S.L. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008, 31:464-468. 10.1016/j.tins.2008.06.006.
102. Pittenger C., Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008, 33:88-109. 10.1038/sj.npp.1301574.
103. Player M.J., Taylor J.L., Weickert C.S., Alonzo A., Sachdev P., Martin D., Mitchell P.B., Loo C.K. Neuroplasticity in depressed individuals compared with healthy controls. Neuropsychopharmacology 2013, 38:2101-2108. 10.1038/npp.2013.126.
104. Price R.B., Nock M.K., Charney D.S., Mathew S.J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol. Psychiatry 2009, 66:522-526. 10.1016/j.biopsych.2009.04.029.
105. Przegaliński E., Tatarczyńska E., Dereń-Wesołek A., Chojnacka-Wojcik E. Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist. Neuropharmacology 1997, 36:31-37. 10.1016/S0028-3908(96)00157-8.
106. Qin Y., Karst H., Joëls M. Chronic unpredictable stress alters gene expression in rat single dentate granule cells. J. Neurochem. 2004, 89:364-374. 10.1111/j. 1471-4159.2003.02332.x.
107. Reisel D., Bannerman D.M., Schmitt W.B., Deacon R.M.J., Flint J., Borchardt T., Seeburg P.H., Rawlins J.N.P. Spatial memory dissociations in mice lacking GluR1. Nat. Neurosci. 2002, 5:868-873. 10.1038/nn910.
108. Riedel G., Platt B., Micheau J. Glutamate receptor function in learning and memory. Behav. Brain Res. 2003, 10.1016/S0166-4328(02)00272-3.
109. Rosa M.L.N.M., Guimarães F.S., Pearson R.C.A., Del Bel E.A. Effects of single or repeated restraint stress on GluR1 and GluR2 flip and flop mRNA expression in the hippocampal formation. Brain Res. Bull. 2002, 59:117-124. 10.1016/S0361-9230(02)00859-6.
110. Sackeim H.A., Freeman J., McElhiney M., Coleman E., Prudic J., Devanand D.P. Effects of major depression on estimates of intelligence. J. Clin. Exp. Neuropsychol. 1992, 14:268-288. 10.1080/01688639208402828.
111. Sagata N., Iwaki A., Aramaki T., Takao K., Kura S., Tsuzuki T., Kawakami R., Ito I., Kitamura T., Sugiyama H., Miyakawa T., Fukumaki Y. Comprehensive behavioural study of GluR4 knockout mice: implication in cognitive function. Genes Brain Behav. 2010, 9:899-909. 10.1111/j.1601-183X.2010.00629.x.
112. Sanacora G., Treccani G., Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012, 62:63-77. 10.1016/j.neuropharm.2011.07.036.
113. Sanchis-Segura C., Borchardt T., Vengeliene V., Zghoul T., Bachteler D., Gass P., Sprengel R., Spanagel R. Involvement of the AMPA receptor GluR-C subunit in alcohol-seeking behavior and relapse. J. Neurosci. 2006, 26:1231-1238. 10.1523/JNEUROSCI.4237-05.2006.
114. Santos S.D., Carvalho a.L., Caldeira M.V., Duarte C.B. Regulation of AMPA receptors and synaptic plasticity. Neuroscience 2009, 158:105-125. 10.1016/j.neuroscience.2008.02.037.
115. Schmitt W.B., Deacon R.M.J., Seeburg P.H., Rawlins J.N.P., Bannerman D.M. A within-subjects, within-task demonstration of intact spatial reference memory and impaired spatial working memory in glutamate receptor-A-deficient mice. J. Neurosci. 2003, 23:3953-3959.
116. Schober D.A., Gill M.B., Yu H., Gernert D.L., Jeffries M.W., Ornstein P.L., Kato A.S., Felder C.C., Bredt D.S. Transmembrane AMPA receptor regulatory proteins and cornichon-2 allosterically regulate AMPA receptor antagonists and potentiators. J. Biol. Chem. 2011, 286:13134-13142. 10.1074/jbc.M110.212522.
117. Schwendt M., Jezová D. Gene expression of two glutamate receptor subunits in response to repeated stress exposure in rat hippocampus. Cell. Mol. Neurobiol. 2000, 20:319-329. 10.1023/A:1007062109386.
118. Shi S.-H., Hayashi Y., Esteban J.A., Malinow R. Subunit-specific rules governing AMPA receptor trafficking to synapses in hippocampal pyramidal neurons. Cell 2001, 105:331-343. 10.1016/S0092-8674(01)00321-X.
119. Shimshek D.R., Bus T., Grinevich V., Single F.N., Mack V., Sprengel R., Spergel D.J., Seeburg P.H. Impaired reproductive behavior by lack of GluR-B containing AMPA receptors but not of NMDA receptors in hypothalamic and septal neurons. Mol. Endocrinol. 2006, 20:219-231. 10.1210/me.2005-0262.
120. Shimshek D.R., Jensen V., Celikel T., Geng Y., Schupp B., Bus T., Mack V., Marx V., Hvalby Ø., Seeburg P.H., Sprengel R. Forebrain-specific glutamate receptor B deletion impairs spatial memory but not hippocampal field long-term potentiation. J. Neurosci. 2006, 26:8428-8440. 10.1523/JNEUROSCI.5410-05.2006.
121. Skolnick P., Popik P., Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol. Sci. 2009, 30:563-569. 10.1016/j.tips.2009.09.002.
122. Slattery D.A., Hudson A.L., Nutt D.J. Invited review: the evolution of antidepressant mechanisms. Fundam. Clin. Pharmacol. 2004, 18:1-21. 10.1111/j. 1472-8206.2004.00195.x.
123. Sprengel R. Role of AMPA receptors in synaptic plasticity. Cell Tissue Res. 2006, 326:447-455. 10.1007/s00441-006-0275-4.
124. Suenaga T., Morinobu S., Kawano K.-I., Sawada T., Yamawaki S. Influence of immobilization stress on the levels of CaMKII and phospho-CaMKII in the rat hippocampus. Int. J. Neuropsychopharmacol. 2004, 7:299-309. 10.1017/S1461145704004304.
125. Svenningsson P., Bateup H., Qi H., Takamiya K., Huganir R.L., Spedding M., Roth B.L., McEwen B.S., Greengard P. Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine. Eur. J. Neurosci. 2007, 26:3509-3517. 10.1111/j. 1460-9568.2007.05952.x.
126. Svenningsson P., Tzavara E.T., Witkin J.M., Fienberg A.A., Nomikos G.G., Greengard P. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc. Natl. Acad. Sci. U.S.A. 2002, 99:3182-3187. 10.1073/pnas.052712799.
127. Tan C.-H., He X., Yang J., Ong W.-Y. Changes in AMPA subunit expression in the mouse brain after chronic treatment with the antidepressant maprotiline: a link between noradrenergic and glutamatergic function?. Exp. Brain Res. 2006, 170:448-456. 10.1007/s00221-005-0228-2.
128. Tokita K., Yamaji T., Hashimoto K. Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacol. Biochem. Behav. 2012, 100:688-704. 10.1016/j.pbb.2011.04.016.
129. Toth E., Gersner R., Wilf-Yarkoni A., Raizel H., Dar D.E., Richter-Levin G., Levit O., Zangen A. Age-dependent effects of chronic stress on brain plasticity and depressive behavior. J. Neurochem. 2008, 107:522-532. 10.1111/j.1471-4159.2008.05642.x.
130. Toyooka K., Iritani S., Makifuchi T., Shirakawa O., Kitamura N., Maeda K., Nakamura R., Niizato K., Watanabe M., Kakita A., Takahashi H., Someya T., Nawa H. Selective reduction of a PDZ protein, SAP-97, in the prefrontal cortex of patients with chronic schizophrenia. J. Neurochem. 2002, 83:797-806. 10.1046/j.1471-4159.2002.01181.x.
131. Trullas R., Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 1990, 185:1-10. 10.1016/0014-2999(90)90204-J.
132. Vekovischeva O.Y., Aitta-Aho T., Echenko O., Kankaanpää A., Seppälä T., Honkanen A., Sprengel R., Korpi E.R. Reduced aggression in AMPA-type glutamate receptor GluR-A subunit-deficient mice. Genes Brain. Behav. 2004, 3:253-265. 10.1111/j.1601-1848.2004.00075.x.
133. Wang J.Q., Arora A., Yang L., Parelkar N.K., Zhang G., Liu X., Choe E.S., Mao L. Phosphorylation of AMPA receptors: mechanisms and synaptic plasticity. Mol. Neurobiol. 2005, 32:237-249. 10.1385/MN:32:3:237.
134. Wiedholz L.M., Owens W.A., Horton R.E., Feyder M., Karlsson R.-M., Hefner K., Sprengel R., Celikel T., Daws L.C., Holmes A. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and schizophrenia-related behaviors. Mol. Psychiatry 2008, 13:631-640. 10.1038/sj.mp.4002056.
135. Willatt L., Cox J., Barber J., Cabanas E.D., Collins A., Donnai D., FitzPatrick D.R., Maher E., Martin H., Parnau J., Pindar L., Ramsay J., Shaw-Smith C., Sistermans E.A., Tettenborn M., Trump D., de Vries B.B.A., Walker K., Raymond F.L. 3Q29 microdeletion syndrome: clinical and molecular characterization of a new syndrome. Am. J. Hum. Genet. 2005, 77:154-160. 10.1086/431653.
136. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005, 52:90-110. 10.1159/000087097.
137. Willner P., Muscat R., Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci. Biobehav. Rev. 1992, 16:525-534. 10.1016/S0149-7634(05)80194-0.
138. Willner P., Towell A., Sampson D., Sophokleous S., Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl.) 1987, 93:358-364. 10.1007/BF00187257.
139. Yoshiya M., Komatsuzaki Y., Hojo Y., Ikeda M., Mukai H., Hatanaka Y., Murakami G., Kawata M., Kimoto T., Kawato S. Corticosterone rapidly increases thorns of CA3 neurons via synaptic/extranuclear glucocorticoid receptor in rat hippocampus. Front. Neural Circuits 2013, 7:191. 10.3389/fncir.2013.00191.
140. Yuen E.Y., Liu W., Karatsoreos I.N., Ren Y., Feng J., McEwen B.S., Yan Z. Mechanisms for acute stress-induced enhancement of glutamatergic transmission and working memory. Mol. Psychiatry 2011, 16:156-170. 10.1038/mp.2010.50.
141. Yuen E.Y., Wei J., Liu W., Zhong P., Li X., Yan Z. Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. Neuron 2012, 73:962-977. 10.1016/j.neuron.2011.12.033.
142. Yüksel C., Öngür D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol. Psychiatry 2010, 68:785-794. 10.1016/j.biopsych.2010.06.016.
143. Zamanillo D., Sprengel R., Hvalby O., Jensen V., Burnashev N., Rozov A., Kaiser K.M., Köster H.J., Borchardt T., Worley P., Lübke J., Frotscher M., Kelly P.H., Sommer B., Andersen P., Seeburg P.H., Sakmann B. Importance of AMPA receptors for hippocampal synaptic plasticity but not for spatial learning. Science 1999, 284:1805-1811. 10.1126/science.284.5421.1805.
144. Zarate C.A., Mathews D., Ibrahim L., Chaves J.F., Marquardt C., Ukoh I., Jolkovsky L., Brutsche N.E., Smith M.A., Luckenbaugh D.A. A randomized trial of a low-trapping nonselective N-methyl-d-aspartate channel blocker in major depression. Biol. Psychiatry 2013, 74:257-264. 10.1016/j.biopsych.2012.10.019.
145. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., Manji H.K. A Randomized Trial of an NMDA antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63:856-864. 10.1001/archpsyc.63.8.856.